Quoin Pharmaceuticals gets FDA Fast Track for QRX003
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 in Peeling Skin Syndrome. The company said it is preparing a Phase 2/3 study in 2H 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Quoin Pharmaceuticals gets FDA Fast Track for QRX003 in Peeling Skin Syndrome
FDA granted Fast Track Designation for QRX003 to treat Peeling Skin Syndrome. Quoin plans to start a Phase 2/3 study in 2H 2026.
Quoin Pharmaceuticals gets FDA Fast Track for QRX003 peeling skin syndrome
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 to treat Peeling Skin Syndrome. It added a second Fast Track designation for QRX003 in addition to Netherton Syndrome.